Abstract:A series of new β-carboline derivatives containing an imidazolium moiety were designed and synthesized via the reaction of β-carboline-1-carboxaldehydes, acetyl chloride, primary amine, and formaldehyde. The antitumor activity of the synthesized compounds was examined against lung carcinoma (A549), gastric carcinoma (BGC-823), murine colon carcinoma (CT-26), liver carcinoma (Bel-7402) and breast carcinoma (MCF-7) cells. The results indicated that most compounds exhibited significant antiproliferative activity, in some cases greater than that of cisplatin, and compound 3z was found to be the most potent antiproliferative agent against A549, BGC823, CT-26, Bel-7402 and MCF-7 cell lines with an IC50 value of 2.7 ± 0.4, 2.7 ± 0.6, 2.4 ± 0.2, 3.2 ± 0.2, and 5.6 ± 0.3 μM, respectively. Combined with favorable in vitro potency, the antitumor efficacies of the selected compounds in mice were also evaluated. Compound 3z exhibited potent antitumor activity with a tumor inhibition rate of 48.6% in sarcoma 180 models. Preliminary investigations on the mechanisms of action revealed that compound 3z could dramatically inhibit EA.hy926 cell tube formation in a dose-dependent manner. Further investigation of the preliminary mechanism of action demonstrated that compound 3z had obvious angiogenesis inhibitory effects in the chicken chorioallantoic membrane (CAM) assay. The results of the docking study showed a good fitting of the new compounds 3o and 3z to the active site of VEGFR-2 with a docking score energy of -11.31 kcal per mole and -11.26 kcal per mole, respectively.

Synthesis and Biological Evaluation of Novel N9-heterobivalent Β-Carbolines As Angiogenesis Inhibitors

Design, Synthesis, and Biological Evaluation of Novel N-Acylhydrazone Bond Linked Heterobivalent β-Carbolines as Potential Anticancer Agents

Synthesis and Biological Evaluation of Novel Alkyl Diamine Linked Bivalent Β-Carbolines As Angiogenesis Inhibitors.

Synthesis and preliminary evaluation of novel alkyl diamine linked bivalent β-carbolines as angiogenesis inhibitors

Synthesis and structure-activity relationships of asymmetric dimeric β-carboline derivatives as potential antitumor agents.

Design, Synthesis, and Antitumor Activity of Β-Carboline- Benzimidazole Hybrids

Synthesis and Antitumor Activities of Novel Bivalent 1-Heterocyclic-β-carbolines Linked by Alkylamino Spacer

Molecular hybrid design, synthesis, in vitro and in vivo anticancer evaluation, and mechanism of action of N-acylhydrazone linked, heterobivalent β-carbolines.

Synthesis and Biological Evaluation of a Novel Class of Β-Carboline Derivatives

Synthesis, Crystal Structure and Antitumor Activity of Novel 5-Chloro-β-carboline Derivatives

Synthesis, pharmacological evaluation, and modeling of novel quaternary ammonium salts derived from β-carboline containing an imidazole moiety as angiogenesis inhibitors

Design, Synthesis and Biological Activity Evaluation of β-Carboline Derivatives Containing Nitrogen Heterocycles

Synthesis and biological evaluation of novel podophyllotoxin analogs as antitumor agents.

Design, Synthesis, and Biological Evaluation of Novel Γ-Carboline Ketones As Anticancer Agents

New β-carboline derivatives containing imidazolium as potential VEGFR2 inhibitors: synthesis, X-ray structure, antiproliferative evaluations, and molecular modeling

Design, Synthesis And Biological Evaluation Of Novel Bromophenol Derivatives Incorporating Indolin-2-One Moiety As Potential Anticancer Agents

Synthesis and Biological Evaluation of a Novel Class of Coumarin Derivatives.

Design, Synthesis, and Biological Evaluation of Novel N-γ-carboline Arylsulfonamides As Anticancer Agents.

Multicomponent synthesis of novel -carboline-fused imidazolium derivatives <i>via</i> the Mannich reaction: cytotoxicity, molecular docking, and mechanistic studies as angiogenesis inhibitors

In silico design of novel tubulin binding 9-arylimino derivatives of noscapine, their chemical synthesis and cellular activity as potent anticancer agents against breast cancer

Synthesis, Biological Evaluation, and Molecular Docking Studies of N-((1,3-diphenyl-1H-pyrazol-4-yl)methyl)aniline Derivatives As Novel Anticancer Agents